Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers

AIM: To examined the efficacy and safety of treatment with boceprevir, PEGylated-interferon and ribavirin (PR) in hepatitis C virus genotype 1 (HCVGT1) PR treatment-failures in Asia. METHODS: The Boceprevir Named-Patient Program provided boceprevir to HCVGT1 PR treatment-failures. Participating phys...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:World J Gastroenterol
Main Authors: Sukeepaisarnjaroen, Wattana, Pham, Tri, Tanwandee, Tewesak, Nazareth, Saroja, Galhenage, Sam, Mollison, Lindsay, Totten, Leanne, Wigg, Alan, Altus, Rosalie, Colman, Anton, Morales, Brenda, Mason, Sue, Jones, Tracey, Leembruggen, Nadine, Fragomelli, Vince, Sendall, Cheryl, Guan, Richard, Sutedja, Dede, Tan, Soek Siam, Dan, Yock Young, Lee, Yin Mei, Luman, Widjaja, Teo, Eng Kiong, Than, Yin Min, Piratvisuth, Teerha, Lim, Seng Gee
Format: Artigo
Jezik:Inglês
Izdano: Baishideng Publishing Group Inc 2015
Teme:
Prospective Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4515847/
https://ncbi.nlm.nih.gov/pubmed/26229408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i28.8660
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki